Table 2.
Numbers, median ages, Overall Survival (OS) and Hazard Ratios (HR) of patients with no rheumatology episodes, and those with three or more rheumatology episodes distributed by diagnostic category (episodes in the year before diagnosis are excluded): HMRN diagnoses 2009–2015, followed-up to 05/07/2018.
| Cases, N(%) | Age1, median(IQR) | 1-year OS, % (95%CI)2 | HR(95%CI), unadjusted | HR(95%CI), adjusted3 | 3-year Overall Survival1, % (95%CI) | HR(95%CI), unadjusted | HR(95%CI), adjusted3 | |
|---|---|---|---|---|---|---|---|---|
| Diffuse large B-cell lymphoma | 1771(100.0) | 70.6(61.1–79.1) | 67.4(65.2–69.5) | 57.4(55.1–59.7) | ||||
| Rheumatology episodes | ||||||||
| None | 1597(90.2) | 70.3(60.7–78.9) | 68.3(65.9–70.5) | 1(ref) | 1(ref) | 58.5(56.0–60.8) | 1(ref) | 1(ref) |
| ≥3 | 111(6.3) | 73.0(66.3–79.7) | 59.5(49.7–67.9) | 1.4(1.0–1.9) | 1.2(0.9–1.6) | 46.6(37.0–55.6) | 1.4(1.1–1.9) | 1.2(0.9–1.6) |
| Z=−3.01, p < 0.01 | χ2 = 4.32, p = 0.04 | χ2 = 6.80, p < 0.01 | ||||||
| Marginal zone lymphoma | 936(100.0) | 72.4(64.4–79.5) | 90.1(88.0–91.8) | 74.5(71.6–77.2) | ||||
| Rheumatology episodes | ||||||||
| None | 840(89.7) | 72.6(64.6–79.6) | 90.1(87.9–92.0) | 1(ref) | 1(ref) | 74.5(71.4–77.3) | 1(ref) | 1(ref) |
| ≥3 | 52(5.6) | 70.9(63.0–77.6) | 90.4(78.4–95.9) | 1.0(0.4–2.4) | 1.3(0.5–3.2) | 78.8(64.9–87.6) | 0.8(0.4–1.5) | 1.0(0.6–1.9) |
| Z = 1.41, p = 0.16 | χ2 = 0.01, p = 0.96 | χ2 = 0.40, p = 0.53 | ||||||
| Follicular lymphoma | 787(100.0) | 65.3(56.2–73.8) | 94.8(93.0–96.1) | 85.4(82.7–87.7) | ||||
| Rheumatology episodes | ||||||||
| None | 726(92.2) | 65.6(56.2–73.8) | 94.6(92.7–96.0) | 1(ref) | 1(ref) | 85.0(82.1–87.4) | 1(ref) | 1(ref) |
| ≥3 | 36(4.6) | 63.0(56.8–75.8) | 97.2(81.9–99.6) | 0.5(0.1–3.7) | 0.6(0.1–4.4) | 91.1(75.0–97.1) | 0.5(0.2–1.7) | 0.6(0.2–1.9) |
| Z = 0.41, p = 0.68 | χ2 = 0.45, p = 0.50 | χ2 = 1.20, p = 0.28 | ||||||
| Chronic lymphocytic leukaemia | 1580(100.0) | 71.1(62.9–78.9) | 90.9(89.4–92.2) | 79.9(77.8–81.8) | ||||
| Rheumatology episodes | ||||||||
| None | 1490(94.3) | 71.0(62.8–78.9) | 90.7(89.2–92.1) | 1(ref) | 1(ref) | 80.2(78.0–82.1) | 1(ref) | 1(ref) |
| ≥3 | 40(2.5) | 75.7(70.6–82.1) | 92.5(78.5–97.5) | 0.8(0.3–2.6) | 0.6(0.2–1.9) | 67.2(50.3–79.5) | 1.8(1.0–3.1) | 1.4(0.8–2.4) |
| Z=−2.71, p < 0.01 | χ2 = 0.11, p = 0.74 | χ2 = 4.30, p = 0.04 | ||||||
| Multiple myeloma | 1760(100.0) | 72.6(64.3–79.8) | 75.1(73.0–77.0) | 55.6(53.2–57.9) | ||||
| Rheumatology episodes | ||||||||
| None | 1647(93.6) | 72.7(64.5–79.8) | 74.9(72.8–76.9) | 1(ref) | 1(ref) | 56.0(53.6–58.4) | 1(ref) | 1(ref) |
| ≥3 | 54(3.1) | 67.6(63.8–76.3) | 75.9(62.2–85.2) | 1.0(0.6–1.7) | 1.1(0.6–1.9) | 48.0(34.2–60.5) | 1.3(0.9–1.8) | 1.4(1.0–2.1) |
| Z = 1.64, p = 0.10 | χ2 = 0.01, p = 0.92 | χ2 = 1.40, p = 0.24 | ||||||
1
Wilcoxon rank-sum test was used to compare age distributions.
2
Log rank test was used to test for survival differences.
3
Adjusted for age.